Tempo Scan Group enters into a partnership with Sino Biopharmaceutical Limited (SBP Group) to strengthen its specialty pharmaceutical activities
PT Tempo Scan Pacific Tbk (“Tempo Scan”) has announced the signing of a joint venture agreement with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Limited (“SBP Group”), one of China’s leading pharmaceutical companies in the field of innovation and research.
This joint venture will establish a joint venture company named PT TEMPO CTTQ BIOPHARMACEUTICAL INDONESIA (“TCBI”). This partnership is a strategic step for Tempo Scan to strengthen its specialty pharmaceutical activities while simultaneously increasing access to modern and innovative medicines for Indonesian patients.
LATEST NEWS: A Review of the Settlement Agreement for Economic Crimes from the Perspective of Dominus Litis
SBP Group is one of the largest research and development (R&D)-based pharmaceutical companies in China, with expertise in the research and development (R&D), manufacturing, and commercialization of innovative medicines, biological medicines, and high-quality branded medicines. The company possesses an extensive portfolio across various treatment areas, including oncology, cardiometabolic disorders, respiratory conditions, and specialist care.
This joint venture is a strategic step for Tempo Scan to strengthen its position as one of the leading integrated healthcare companies in Indonesia, while simultaneously expanding its portfolio of specialist pharmaceutical products and innovative medicines and consolidating its established reputation for well-known OTC medicines and consumer health products.
Through a combination of generic products and modern, innovative pharmaceutical products, the joint venture aims to increase Indonesian patients’ access to modern, innovative, and high-quality medicines, thereby expanding treatment options in the domestic market.
In addition to increasing patient access to modern medicines, this collaboration is also expected to foster knowledge exchange in manufacturing, develop the capabilities of the Indonesian pharmaceutical industry, and strengthen the Indonesian healthcare system in the long term.
LATEST NEWS: French Ambassador Impressed by Nias Megalithic Sites
Moreover, the establishment of this joint venture is clear evidence that Indonesia remains attractive to foreign investors as an investment destination. Tempo Scan has 16 production facilities and a nationwide distribution network of 238 locations. Tempo Scan is a 100% Indonesian company that produces and sells well-known brands such as Bodrex, Hemaviton, NEO Rheumacyl, Oskadon, MY BABY, Marina, Vidoran, and others.
As one of the largest integrated healthcare ecosystems in Indonesia, Tempo Scan possesses expertise in research and development, production, and distribution. This expertise makes Tempo Scan a competent strategic partner in accelerating Indonesians’ access to the pharmaceutical products they need.
Following its establishment, PT TEMPO CTTQ BIOPHARMACEUTICAL INDONESIA (TCBI) aims to gradually launch various specialized and innovative products in the coming years, including products that have already been approved and products currently in the registration process. This joint venture represents a strategic step by Tempo Scan to build a platform for specialty pharmaceutical products and innovative healthcare in Indonesia, with the aim of increasing patient access to and freedom of choice regarding modern, high-quality medicines.
Handojo S Muljadi, Executive Chairman and Co-founder of Tempo Scan Group, stated that the signing of the joint venture with SBP Group, Chia Tai Tianqing Pharmaceutical Group Co., Ltd (cTTQ), is a strategic step for Tempo Scan to strengthen the company’s biotechnology and specialty pharmaceutical activities.
LATEST NEWS: Kahiyang Ayu visits Japanese Consulate General in Medan and presents the charm of North Sumatra
“Through this partnership, we hope to increase access to and choice of medicines for patients in Indonesia, particularly regarding the availability of modern, high-quality medicines. We also hope to play a role in the development of the national pharmaceutical industry by collaborating with global partners with strong research and innovation capabilities. Equally important is that this joint venture clearly demonstrates that Indonesia is an attractive long-term investment destination for foreign investors,” said Muljadi.
Philip Duong, President International at SBP Group, stated that the establishment of TCBI is a significant milestone in SBP Group’s international development strategy. “We are delighted to partner with Tempo Scan, one of the leading companies in the Indonesian healthcare sector.
By combining SBP Group’s innovative drug portfolio and development capabilities with Tempo Scan’s local expertise and commercial reach, we hope to accelerate Indonesian patients’ access to innovative therapies while simultaneously contributing to the strengthening of the Indonesian healthcare system.”
With the establishment of PT Tempo CTTQ Biopharmaceutical Indonesia, Tempo Scan confirms its commitment to continuously providing innovative healthcare solutions to the Indonesian population while simultaneously strengthening the competitiveness of the national pharmaceutical industry through strategic partnerships with reliable international partners. ***rel
